title: Study of a new tumor marker, CYFRA 21-1, in malignant and nonmalignant diseases.
abstract: The diagnostic value of a new tumor marker, CYFRA 21-1, was studied in the sera of 50 controls, 206 patients with benign diseases and 469 patients with malignancies. Fifty controls showed mean serum concentrations of 1.2 +/- 0.5 ng/ml. Using 3.3 ng/ml as the cutoff, abnormal CYFRA levels were found in 13.1% of patients with benign diseases, mainly in those with liver cirrhosis (29.4%) or renal failure (20.8%), and in 44.4% (180/405) of patients with active cancer. Neither healthy subjects nor no evidence of disease (64 cases) patients had serum levels higher than this limit. CYFRA 21-1 results were significantly higher in patients with active cancer than in those with benign diseases or without active tumors (p < 0.0001). CYFRA serum levels were significantly higher in patients with metastases (59.5%) than in those with locoregional disease (33.7%; p < 0.001). CYFRA 21-1 sensitivity in patients with lung cancer was related to tumor histology with abnormal levels in 65.6% of patients with non-small cell lung cancer and in 25% of patients with small cell lung cancer (p < 0.0001). In breast cancer, CYFRA 21-1 concentrations were significantly higher in patients with metastases and in patients with primary tumors but with nodal involvement (p < 0.001).
authors.affiliation: Laboratory of Clinical Biochemistry, Unit for Cancer Research, Hospital Clínico y Provincial, Medical School, Barcelona, Spain.
authors.forename: R
authors.initials: R
authors.lastname: Molina
authors.forename: C
authors.initials: C
authors.lastname: Agusti
authors.forename: X
authors.initials: X
authors.lastname: Filella
authors.forename: J
authors.initials: J
authors.lastname: Jo
authors.forename: J
authors.initials: J
authors.lastname: Joseph
authors.forename: N
authors.initials: N
authors.lastname: Giménez
authors.forename: A M
authors.initials: AM
authors.lastname: Ballesta
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood; D002276:Carcinoid Tumor / Q000097:blood; D015179:Colorectal Neoplasms / Q000097:blood; D004194:Disease; D005260:Female; D006258:Head and Neck Neoplasms / Q000097:blood; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood; D008175:Lung Neoplasms / Q000097:blood; D008297:Male; D009367:Neoplasm Staging; D009369:Neoplasms / Q000097:blood* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood; D012016:Reference Values
chemical_list: D014408:Biomarkers, Tumor